Technical Analysis for IMPL - Impel NeuroPharma, Inc.

Grade Last Price % Change Price Change
F 0.04 -27.27% -0.02
IMPL closed down 27.27 percent on Wednesday, December 20, 2023, on 59 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Mar 22
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -27.27%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Impel NeuroPharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Parkinson's Disease Autism Spectrum Disorder Migraine Central Nervous System Disease Prodrugs Treatment Of Migraine Combination Drugs Carbidopa L Dopa

Is IMPL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.2
52 Week Low 0.0212
Average Volume 1,228,273
200-Day Moving Average 0.97
50-Day Moving Average 0.34
20-Day Moving Average 0.41
10-Day Moving Average 0.28
Average True Range 0.11
RSI (14) 31.51
ADX 32.78
+DI 21.91
-DI 29.00
Chandelier Exit (Long, 3 ATRs) 0.72
Chandelier Exit (Short, 3 ATRs) 0.36
Upper Bollinger Bands 0.82
Lower Bollinger Band 0.01
Percent B (%b) 0.04
BandWidth 196.79
MACD Line -0.07
MACD Signal Line -0.02
MACD Histogram -0.0497
Fundamentals Value
Market Cap 956 Thousand
Num Shares 23.9 Million
EPS -3.12
Price-to-Earnings (P/E) Ratio -0.01
Price-to-Sales 0.05
Price-to-Book 18.46
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.08
Resistance 3 (R3) 0.08 0.07 0.08
Resistance 2 (R2) 0.07 0.05 0.07 0.07
Resistance 1 (R1) 0.05 0.05 0.05 0.05 0.07
Pivot Point 0.04 0.04 0.03 0.04 0.04
Support 1 (S1) 0.02 0.03 0.02 0.03 0.01
Support 2 (S2) 0.01 0.02 0.01 0.01
Support 3 (S3) 0.00 0.01 0.00
Support 4 (S4) 0.00